Doctors Without Borders (MSF) is calling on Eli Lilly, Novo Nordisk and Sanofi to immediately reduce the price of insulin ...

general manager of Novo Nordisk UK. "Our smart connected insulin pens aim to empower people to better understand their diabetes management, have more informed conversations with their doctor and ...

A s a teen, Lecritia Roberts injected herself with insulin using a glass vial and a syringe to manage her type 1 diabetes, ...

Novo Nordisk has signed off on a $285 million biobucks deal with fellow Denmark-based company Ascendis Pharma to help the Wegovy manufacturer develop a once-monthly GLP-1 receptor agonist.

With the rise in the popularity of weight loss drugs like ‘Wegovy’ and ‘Ozempic,’ we’re learning a counterfeit market has ...

Novo Nordisk landed in hot water with the FDA following an inspection at one of the drugmaker’s key semaglutide and insulin manufacturing plants this past spring. | The FDA issued a ...

Novo Nordisk, the pharma giant behind Ozempic and Wegovy, has surprising love story origins. The founders, a married couple, ...

Novo Nordisk remains a sell due to increased competition ... with a 54.8% market share in GLP-1 and a 43.9% market share in insulin (33.8% total diabetes market share). As this share has grown ...

Novo Nordisk’s blockbuster Wegovy weight-loss drug beat sales expectations in the third quarter, sending shares 8.5% higher in early trade. Soaring popularity for its obesity drug has seen ...

A Novo Nordisk official said the company makes more than a dozen insulin products and more than 800 million insulin pens a year. "Not only are we not winding down our work for people living with ...

Novo Nordisk's Q3 2024 sales rose 21% YoY to $ ... Wegovy sales soared 81% YoY to DKK17.3 billion; Obesity care grew 55%, while insulin sales rose 10%, boosting overall portfolio strength.